Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. [electronic resource]
Producer: 20130204Description: 1785-95 p. digitalISSN:- 1460-2105
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Tumor -- genetics
- Colorectal Neoplasms -- drug therapy
- Confounding Factors, Epidemiologic
- Cost-Benefit Analysis
- Decision Support Techniques
- ErbB Receptors -- antagonists & inhibitors
- Female
- Genetic Testing -- economics
- Humans
- Male
- Middle Aged
- Mutation
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras)
- Quality-Adjusted Life Years
- Research Design
- United States
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.